Adverse events
| Event and grade . | Total . | Age of <65 y . | Age of ≥65 y . | P value . |
|---|---|---|---|---|
| CRS, n (%) | 156 | 81 (51.9) | 75 (48.1) | |
| Any, n (%) | 132 (84.6) | 66 (81.5) | 66 (88.0) | .53 |
| Grade ≥3, n (%) | 3 (1.9) | 2 (2.4) | 1 (1.2) | |
| Median time to maximum severity, d (range) | 1 (0-21) | 1 (0-14) | 1 (0-21) | .28 |
| ICANS | ||||
| Any, n (%) | 30 (23.8) | 11 (13.6) | 19 (25.3) | .14 |
| Grade ≥3, n (%) | 7 (4.5) | 4 (4.9) | 3 (4.0) | |
| Median time to maximum severity, d (range) | 2 (0-24) | 3 (0-24) | 1.5 (0-4) | .054∗ |
| Neutropenia (grade ≥3) | ||||
| 30 d, n = 154, n (%) | 48 (31.4) | 29 (36.3) | 19 (26.0) | .17 |
| 60 d, n = 117, n (%) | 28 (23.9) | 18 (30.0) | 10 (17.5) | .11 |
| 90 d, n = 130, n (%) | 13 (10.0) | 6 (8.8) | 7 (11.3) | .64 |
| Anemia (grade ≥3) | ||||
| 30 d, n = 154, n (%) | 29 (18.8) | 13 (16.3) | 16 (21.6) | .39 |
| 60 d, n = 118, n (%) | 18 (15.3) | 11 (18.0) | 7 (12.3) | .39 |
| 90 d, n = 131, n (%) | 13 (9.9) | 6 (8.7) | 7 (11.3) | .62 |
| Thrombocytopenia (grade ≥3) | ||||
| 30 d, n = 154, n (%) | 44 (28.6) | 23 (28.8) | 21 (28.4) | .96 |
| 60 d, n = 118, n (%) | 42 (35.6) | 21 (34.4) | 21 (36.8) | .78 |
| 90 d, n = 131, n (%) | 31 (23.7) | 16 (23.2) | 15 (24.2) | .89 |
| Supportive care for cytopenias | ||||
| G-CSF | ||||
| 1-30 d, n = 156, n (%) | 115 (73.7) | 59 (72.8) | 56 (74.7) | .80 |
| 31-60 d, n = 153, n (%) | 57 (37.3) | 30 (38.5) | 27 (36.0) | .75 |
| 61-90 d, n = 149, n (%) | 23 (15.4) | 12 (15.6) | 22 (15.3) | .96 |
| Blood transfusion | ||||
| 1-30 d, n = 156, n (%) | 72 (46.2) | 39 (48.2) | 33 (44.0) | .60 |
| 31-60 d, n = 153, n (%) | 32 (20.9) | 17 (21.8) | 15 (20.0) | .79 |
| 61-90 d, n = 149, n (%) | 18 (12.1) | 9 (11.7) | 9 (12.5) | .88 |
| Platelet transfusion | ||||
| 1-30 d, n = 156, n (%) | 58 (37.2) | 30 (37.0) | 28 (37.3) | .97 |
| 31-60 d, n = 153, n (%) | 33 (21.6) | 19 (24.4) | 14 (18.7) | .39 |
| 61-90 d, n = 149, n (%) | 13 (8.7) | 6 (7.8) | 7 (9.7) | .68 |
| IVIG infusion, n (%) | 50 (32.1) | 22 (27.2) | 28 (37.3) | .17 |
| Hospitalization | ||||
| Median hospital stay, d (range) | 9 (5-69) | 9 (5-68) | 9 (6-69) | .84 |
| Intensive care unit stay, n (%) | 9 (5.8) | 6 (7.4) | 3 (4.0) | .36 |
| Event and grade . | Total . | Age of <65 y . | Age of ≥65 y . | P value . |
|---|---|---|---|---|
| CRS, n (%) | 156 | 81 (51.9) | 75 (48.1) | |
| Any, n (%) | 132 (84.6) | 66 (81.5) | 66 (88.0) | .53 |
| Grade ≥3, n (%) | 3 (1.9) | 2 (2.4) | 1 (1.2) | |
| Median time to maximum severity, d (range) | 1 (0-21) | 1 (0-14) | 1 (0-21) | .28 |
| ICANS | ||||
| Any, n (%) | 30 (23.8) | 11 (13.6) | 19 (25.3) | .14 |
| Grade ≥3, n (%) | 7 (4.5) | 4 (4.9) | 3 (4.0) | |
| Median time to maximum severity, d (range) | 2 (0-24) | 3 (0-24) | 1.5 (0-4) | .054∗ |
| Neutropenia (grade ≥3) | ||||
| 30 d, n = 154, n (%) | 48 (31.4) | 29 (36.3) | 19 (26.0) | .17 |
| 60 d, n = 117, n (%) | 28 (23.9) | 18 (30.0) | 10 (17.5) | .11 |
| 90 d, n = 130, n (%) | 13 (10.0) | 6 (8.8) | 7 (11.3) | .64 |
| Anemia (grade ≥3) | ||||
| 30 d, n = 154, n (%) | 29 (18.8) | 13 (16.3) | 16 (21.6) | .39 |
| 60 d, n = 118, n (%) | 18 (15.3) | 11 (18.0) | 7 (12.3) | .39 |
| 90 d, n = 131, n (%) | 13 (9.9) | 6 (8.7) | 7 (11.3) | .62 |
| Thrombocytopenia (grade ≥3) | ||||
| 30 d, n = 154, n (%) | 44 (28.6) | 23 (28.8) | 21 (28.4) | .96 |
| 60 d, n = 118, n (%) | 42 (35.6) | 21 (34.4) | 21 (36.8) | .78 |
| 90 d, n = 131, n (%) | 31 (23.7) | 16 (23.2) | 15 (24.2) | .89 |
| Supportive care for cytopenias | ||||
| G-CSF | ||||
| 1-30 d, n = 156, n (%) | 115 (73.7) | 59 (72.8) | 56 (74.7) | .80 |
| 31-60 d, n = 153, n (%) | 57 (37.3) | 30 (38.5) | 27 (36.0) | .75 |
| 61-90 d, n = 149, n (%) | 23 (15.4) | 12 (15.6) | 22 (15.3) | .96 |
| Blood transfusion | ||||
| 1-30 d, n = 156, n (%) | 72 (46.2) | 39 (48.2) | 33 (44.0) | .60 |
| 31-60 d, n = 153, n (%) | 32 (20.9) | 17 (21.8) | 15 (20.0) | .79 |
| 61-90 d, n = 149, n (%) | 18 (12.1) | 9 (11.7) | 9 (12.5) | .88 |
| Platelet transfusion | ||||
| 1-30 d, n = 156, n (%) | 58 (37.2) | 30 (37.0) | 28 (37.3) | .97 |
| 31-60 d, n = 153, n (%) | 33 (21.6) | 19 (24.4) | 14 (18.7) | .39 |
| 61-90 d, n = 149, n (%) | 13 (8.7) | 6 (7.8) | 7 (9.7) | .68 |
| IVIG infusion, n (%) | 50 (32.1) | 22 (27.2) | 28 (37.3) | .17 |
| Hospitalization | ||||
| Median hospital stay, d (range) | 9 (5-69) | 9 (5-68) | 9 (6-69) | .84 |
| Intensive care unit stay, n (%) | 9 (5.8) | 6 (7.4) | 3 (4.0) | .36 |
G-CSF, growth-colony stimulating factor; IVIG, Intravenous immunoglobulin.
Borderline significance between age groups, P < .10.